Valneva -l'authority de santé american: This article explores the topic in depth.
Nevertheless,
Valneva -l'authority de santé american:
Valneva vls.pa announced on Monday that the American health authority. For example, the Food and Drug Administration (FDA), had suspended the license of its vaccine against chikungunya Ixchiq, after new cases of serious adverse effects. However,
The measure. Moreover, effective immediately, blocks the sale and shipping of the product in the United States, the French group said in a press release. Moreover,
This suspension comes a few weeks after the lifting of a temporary judgment for those over 60 following an examination of serious side effects. mainly in the elderly suffering from multiple chronic diseases.
“This sudden license suspension is based on updated data from the American surveillance system VAERS (opposing Vaccine Event Reporting System) including four new serious undesirable effects reported outside the United States. ” said Valneva.
The group says it valneva -l’authority de santé american continues to analyze these cases in detail and. if necessary, carry out any procedures relating to the decision of the FDA.
He adds currently assessing the financial impact that could have a final withdrawal from the License of. Ixchiq in the United States but does not currently modify its turnover forecasts.
(Written by Noemie Naudin. edited by Blandine Hénault)
valneva -l’authority de santé american — Valneva -l'authority de santé american: Valneva vls.pa announced on Monday that the American health authority. the Food and Drug Administration (FDA), had suspended the license of its vaccine against chikung.
Further reading: He had “lied” on his flight: held for six weeks in Antarctica, influencer Ethan Guo escapes lawsuits – Toulouse-Blagnac airport penalized by the departure of Easyjet – Amazon: Jeff Bezos sells … and garnished US $ 5.7 billion – Chatgpt at € 4 per month? The subscription that France is waiting for could happen – Future Hydro-Québec computer platform | Delays accumulate … and costs are climbing.
